Form 4: BMY Director Derica Rice Boosts Equity Holdings

Bristol Myers Squibb Director Derica W. Rice acquired 3,996.367 Deferred Share Units, increasing her beneficial ownership to 39,324.809 units, aligning interests with shareholders.

Summary

• Derica W. Rice, a Director of Bristol-Myers Squibb Company (BMY), acquired 3,996.367 Deferred Share Units (DSUs).
• The transaction date for the acquisition was February 1, 2026.
• Each DSU is convertible into one share of common stock upon settlement.
• The DSUs become settleable when the reporting person ceases to be a director or at a future date previously specified.
• The acquisition price per DSU was $55.05.
• Following this transaction, Derica W. Rice beneficially owns a total of 39,324.809 Deferred Share Units.
• The total value of the acquired DSUs is approximately $219,970.20 (3,996.367 units * $55.05/unit).
• The total beneficial ownership includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine event. While not indicative of a major strategic shift, the increase in director equity holdings through compensation is a positive signal of alignment and commitment.

Positives

• A director increasing their equity stake, even through compensation, generally signals confidence in the company's future performance and aligns management interests with those of shareholders.
• The acquisition of Deferred Share Units is a common form of non-employee director compensation, indicating a structured approach to incentivizing long-term commitment.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction. It primarily reports an insider transaction related to director compensation.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving equity grants or acquisitions by directors, are common in the pharmaceutical industry as a means of executive and board compensation. These transactions typically aim to align the interests of company leadership with long-term shareholder value. While this specific transaction is routine, it contributes to the overall picture of insider holdings at Bristol Myers Squibb, a major player in the global pharmaceutical market, competing with peers like Pfizer, Merck, and Johnson & Johnson.

Stakeholder Impact

• Shareholders: The transaction increases the director's equity stake, potentially enhancing alignment of interests between the board and shareholders, which can be viewed positively for corporate governance and long-term value creation.

Next Steps

• The Deferred Share Units will be converted into shares of common stock upon settlement, which occurs when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of deferred share units by a director as part of their compensation. Such transactions are common and do not typically provide new fundamental information that would warrant a change in an investment thesis for a company of Bristol Myers Squibb's size and market position. Therefore, a 'hold' recommendation is appropriate, as this filing alone does not alter the company's underlying value proposition or risk profile.

Keywords

Bristol Myers Squibb, BMY, Form 4, Insider Transaction, Director Compensation, Deferred Share Units, Equity Holdings, Beneficial Ownership, Pharmaceuticals